JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Kim, B.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Kim, B.-T.
Journal of Nuclear Medicine Vol. 46 No. 3 472-478
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Radiolabeled RGD Uptake and {alpha}v Integrin Expression Is Enhanced in Ischemic Murine Hindlimbs

Kyung-Han Lee, MD1, Kyoung-Ho Jung, BA1, Sung-Hee Song, MS1, Dong Hyun Kim, BA1, Byung Chul Lee, PhD2, Hyun Ju Sung, MS2, Yu-Mi Han, MS3, Yearn Seong Choe, PhD1, Dae Yoon Chi, PhD2 and Byung-Tae Kim, MD1

1 Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 Department of Chemistry, College of Medicine, Inha University, Inchun, Korea
3 Department of Anatomy, College of Medicine, Inha University, Inchun, Korea

Radiolabeled RGD peptides that target {alpha}vß3 integrin are promising tracers for imaging tumor angiogenesis. Integrins and angiogenesis also play important roles in healing of ischemic lesions. Thus, we investigated the biodistribution of radiolabeled RGD and expression of {alpha}v integrin in a mouse model of hindlimb ischemia. Methods: 125I-3-Iodo-D-Tyr4-cyclo(-Arg-Gly-Asp-D-Tyr-Val-) (125I-c(RGD(I)yV)) was synthesized and tested for endothelial binding. Hindlimb ischemia was induced in ICR mice through femoral artery ablation, and perfusion was measured with laser Doppler blood flowmetry. 125I-c(RGD(I)yV) biodistribution was evaluated in control animals (n = 7) and ischemic models on day 3, 8, or 14 (n = 6 each). Control experiments were performed using a radiolabeled peptide with a scrambled amino acid sequence (125I-GfVGV). Microsections of hindlimb tissue were immunostained for {alpha}v integrin expression and stained with alkaline phosphatase to localize vascular endothelial cells. Results: 125I-c(RGD(I)yV) retained specific binding to human umbilical vein endothelial cells. Perfusion in ischemic hindlimbs immediately fell to 10% ± 4% of contralateral levels and gradually recovered to 22% ± 11% and 64% ± 9% on days 8 and 14, respectively. 125I-c(RGD(I)yV) uptake in ischemic muscles significantly increased from a control level of 0.16 ± 0.05 %ID/g (percentage injected dose per gram of tissue) to 0.85 ± 0.76 %ID/g at day 3, 0.43 ± 0.23 %ID/g at day 8, and 0.43 ± 0.28 %ID/g at day 14 (all P < 0.05). Ischemic muscle-to-lung count ratios had a virtually identical trend: 0.42 ± 0.25 for controls, 2.34 ± 1.70 at day 3 (P < 0.02), 1.46 ± 0.52 at day 8 (P < 0.001), and 1.39 ± 0.94 at day 14 (P < 0.02). In contrast, uptake of the control peptide in ischemic hindlimbs was not different from that of controls. Immunohistochemistry revealed substantially increased {alpha}v integrin staining in ischemic hindlimb tissue. Conclusion: Radioiodine RGD uptake is significantly enhanced in ischemic hindlimbs of a mouse model, and is accompanied by an increase in {alpha}v integrin expression. Further investigation is thus warranted to illuminate the potential role of radiolabeled RGD for noninvasive monitoring of peripheral ischemic lesions.

Key Words: RGD peptides • integrin • ischemia • angiogenesis




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
H. F. Langer, R. Haubner, B. J. Pichler, and M. Gawaz
Radionuclide imaging a molecular key to the atherosclerotic plaque.
J. Am. Coll. Cardiol., July 1, 2008; 52(1): 1 - 12.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol ImgHome page
A. J. Sinusas
Targeted Imaging Offers Advantages Over Physiological Imaging for Evaluation of Angiogenic Therapy
J. Am. Coll. Cardiol. Img., July 1, 2008; 1(4): 511 - 514.
[Full Text] [PDF]


Home page
JNMHome page
J. M. Jeong, M. K. Hong, Y. S. Chang, Y.-S. Lee, Y. J. Kim, G. J. Cheon, D. S. Lee, J.-K. Chung, and M. C. Lee
Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice
J. Nucl. Med., May 1, 2008; 49(5): 830 - 836.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. K. Willmann, K. Chen, H. Wang, R. Paulmurugan, M. Rollins, W. Cai, D. S. Wang, I. Y. Chen, O. Gheysens, M. Rodriguez-Porcel, et al.
Monitoring of the Biological Response to Murine Hindlimb Ischemia With 64Cu-Labeled Vascular Endothelial Growth Factor-121 Positron Emission Tomography
Circulation, February 19, 2008; 117(7): 915 - 922.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.